[This corrects the article DOI: 10.1371/journal.pone.0164455.].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300180 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0172184 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial.
Lancet HIV
February 2024
AMS-PHPT Research Collaboration, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand; Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand. Electronic address:
Background: Existing solid antiretroviral fixed-dose combination formulations are preferred over liquid formulations in children, but their suitability for neonates is unknown. We evaluated the pharmacokinetics and safety of paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates.
Methods: In this open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial, generic abacavir- lamivudine (120:60 mg) double-scored dispersible tablets and lopinavir boosted with ritonavir (40:10 mg) granules were studied.
Coronary Microcirculatory Dysfunction in People With HIV and Its Association With Antiretroviral Therapy.
J Am Heart Assoc
November 2023
Cardiovascular Imaging Program, Departments of Medicine and Radiology Brigham and Women's Hospital, Harvard Medical School Boston MA USA.
Background: HIV infection and abacavir-containing antiretroviral regimens are associated with vascular endothelial dysfunction and increased cardiovascular risk. Positron emission tomography (PET)-derived myocardial blood flow reserve (MBFR), the ratio of vasodilator stress to rest myocardial blood flow, is a well-validated measure of coronary microvascular health and marker of cardiovascular risk. Our objective was to compare MBFR among people with HIV (PWH) with matched non-HIV controls and to assess whether switching from dolutegravir/lamivudine/abacavir to the non-abacavir regimen bictegravir/emtricitabine/tenofovir alafenamide (TAF) would improve MBFR.
View Article and Find Full Text PDFCorrection to: efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks.
BMC Pharmacol Toxicol
October 2023
Internal Medicine Service, Hospital Costa del Sol, Autovía A-7, km 187, Marbella, 29603, Spain.
Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children.
Pediatr Infect Dis J
March 2022
ViiV Healthcare, Research Triangle Park, NC.
Background: The World Health Organization (WHO) 2019 antiretroviral treatment guidelines recommend use of optimal treatment regimens in all populations. Dolutegravir-based regimens are the preferred first-line and second-line treatment in infants and children with HIV 4 weeks of age and above. There is an urgent need for optimal pediatric formulations of dolutegravir as single-entity (SE) and fixed-dose combination (FDC) to ensure correct dosing and adherence for swallowing and palatability.
View Article and Find Full Text PDFCorrigendum to: Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients.
Open Forum Infect Dis
December 2019
Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Switzerland.
[This corrects the article DOI: 10.1093/ofid/ofz330.][This corrects the article DOI: 10.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!